-+ 0.00%
-+ 0.00%
-+ 0.00%
Fosun Pharmaceutical (02196): FXR0906 injection to treat hypertriglyceridemia begins phase II clinical trial in China
Share
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, Fosun Pharmaceutical Industry Development (Shenzhen) Co., Ltd., a holding subsidiary of the company, launched a phase II clinical trial on the use of FXR0906 injections to treat hypertriglyceridemia in China.


Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending